[Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
23 patients with hyperlipidemia and hyperuricemia received acetamidoethyl-(4-chlorophenyl)-(trifluoromethylphenoxy)-acetate (halofenate), a clofibrate derivative, and probenecid or probenecid and placebo over 36 weeks following a placebo period of 6 weeks. Halofenate compared with probenecid lowered elevated serum uric acid levels satisfactorily to a therapeutic level between 5 and 6 mg/100 ml. Serum triglyceride levels were not always lowered sufficiently, serum cholesterol levels were not influenced.
D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006016:Glycolates / Q000627:therapeutic use*; D006218:Halofenate / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D011339:Probenecid / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood*
D006016:Glycolates; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D006218:Halofenate; D011339:Probenecid
Die Behandlung von Hyperlipidämie und Hyperurikämie mit 2-Acetamidoäthyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetat (Halofenat), einem Derivat des Clofibrat